ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailMenu BurgerPositive ArrowIcon PrintIcon SearchSite TitleTitle ChevronIcon Twitter
Science

Japan to begin transplants using donor iPS cells

Shinya Yamanaka, center, at a news conference Monday.

OSAKA -- Four Japanese institutions will collaborate on transplanting tissue grown from induced pluripotent stem cells taken from donors into patients suffering from age-related macular degeneration, a hard-to-cure eye disease.

The initiative, announced Monday, will break new ground in that the cost of transplanting iPS-derived tissue will be significantly reduced by using stocked cells provided by donors, instead of using the patients' own cells as in a previous case involving a sufferer of the same disease.

Under the partnership agreed on May 30, Kyoto University will provide iPS cells resistant to immunological rejection in the treatment and the government-affiliated Riken research institute will grow them into retinal cells. Osaka University and the Kobe City Medical Center General Hospital will implant these cells into patients as early as the first half of 2017.

"We formed a solid tag team between four institutions, which I feel will be a force to be reckoned with," Kyoto University professor Shinya Yamanaka told a news conference Monday.

Clinical research will also run concurrently using tissue grown from the patients' own iPS cells. About 20 candidates in all will receive transplants.

In 2014, Riken performed the world's first transplant of iPS-derived retinal tissue, with a Japanese woman suffering from macular degeneration on the receiving end. But because the patient provided her own iPS cells, costs related to that procedure reportedly climbed to around 100 million yen ($931,000). Using donor iPS cells is expected to drive down costs to a fifth or lower.

A transplant on a second patient was called off after the discovery of a genetic mutation in the patient's iPS cells. 

(Nikkei)

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends January 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media